> trials = read.csv("clinical_trial",stringsAsFactors = FALSE)
Error in file(file, "rt") : cannot open the connection
In addition: Warning message:
In file(file, "rt") :
  cannot open file 'clinical_trial': No such file or directory
> trials = read.csv("clinical_trial.csv",stringsAsFactors = FALSE)
> str(trials)
'data.frame':   1860 obs. of  3 variables:
 $ title   : chr  "Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962)." "Cell mediated immune status in malignancy--pretherapy and post-therapy assessment." "Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breas"| __truncated__ "Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for "| __truncated__ ...
 $ abstract: chr  "" "Twenty-eight cases of malignancies of different kinds were studied to assess T-cell activity and population bef"| __truncated__ "BACKGROUND: Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with un"| __truncated__ "BACKGROUND: Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a co"| __truncated__ ...
 $ trial   : int  1 0 1 1 1 0 1 0 0 0 ...
> library(tm)
> corpusTitle = VCorpus(VectorSource(trials$title))
> corpusTitle = tm_map(corpusTitle, content_transformer(tolower))
> corpusTitle = tm_map(corpusTitle, removePunctuation)
> corpusTitle = tm_map(corpusTitle, removeWords, stopwords("english"))
> corpusTitle = tm_map(corpusTitle, stemDocument)
> dtmTitle = DocumentTermMatrix(corpusTitle)
> dtmTitle = removeSparseTerms(dtmTitle, 0.95)
> dtmTitle = as.data.frame(as.matrix(dtmTitle))
> corpusAbstract = VCorpus(VectorSource(trials$abstract))
> corpusAbstract = tm_map(corpusAbstract,content_transformer(tolower))
> corpusAbstract = tm_map(corpusAbstract, removePunctuation)
> corpusAbstract = tm_map(corpusAbstract, removeWords,stopwords("english"))
> dtmAbstract = DocumentTermMatrix(corpusAbstract)
> dtmAbstract = removeSparseTerms(dtmAbstract,0.95)
> dtmAbstract = as.data.frame(as.matrix(dtmAbstract))
> csAbstract = colSums(dtmAbstract)
> csAbstract
            0001              001              005              100              500    5fluorouracil        according         achieved           active 
             249              162              124              225              169              208              174              186              137 
        activity         addition       additional         adjuvant     administered   administration         advanced          adverse              age 
             309              227              172             1161              306              216              545              250              360 
          agents              aim            alone             also         although            among         analyses         analysis         analyzed 
             136              130              472              364              191              365              141              587              110 
           andor              arm             arms        aromatase           assess         assessed         assigned       associated        available 
             128              744              294              171              154              269              411              504              103 
        axillary       background            based         baseline          benefit           better             bone           breast              can 
             292              397              122              340              475              186              510             3854              191 
          cancer        carcinoma            cases             cell            cells           change          changes  characteristics     chemotherapy 
            3568              215              201              154              205              163              241              109             2337 
        clinical              cmf      combination         combined           common          compare         compared        comparing         complete 
             835              586              690              162              162              167              941              111              411 
       completed       conclusion      conclusions        conducted       confidence       considered          control          courses            cycle 
             115              490              352              170              240              104              429              172              220 
          cycles cyclophosphamide            daily             data              day             days            death         decrease        decreased 
             734              632              412              405              470              775              140              130              185 
    demonstrated           design        determine       determined        developed              dfs       difference      differences        different 
             170              129              217              101              139              310              504              358              246 
         disease      diseasefree          distant        docetaxel             dose            doses      doubleblind      doxorubicin             drug 
             939              364              149              514              794              288              142              486              204 
           drugs              due         duration            early           effect        effective          effects         efficacy            eight 
             128              154              320              325              423              303              525              576              124 
          either         eligible              end        endocrine         endpoint         enrolled          entered       epirubicin         estrogen 
             532              176              218              266              126              195              109              338              375 
       evaluable         evaluate        evaluated       evaluation           events            every         evidence      experienced       expression 
             212              223              299              140              339              487              119              149              310 
          factor          factors          failure         findings            first        firstline             five     fluorouracil         followed 
             296              256              244              152              421              182              173              215              366 
       following         followup            found             four            given            grade          greater            group           groups 
             247              494              237              369              374              529              279             1879              780 
          growth           hazard             her2             high           higher          hormone          however            human          hundred 
             208              254              314              309              415              287              339              135              195 
             iii          improve         improved      improvement        incidence         included        including         increase        increased 
             266              115              208              151              280              310              186              243              364 
     independent         infusion          initial         interval     investigated            least             less            level           levels 
             135              206              143              279              123              177              351              152              590 
            life            local           longer              low            lower            lymph       mastectomy              may              mbc 
             178              163              193              196              222              249              165              413              276 
            mean         measured           median       metastases       metastatic          methods     methotrexate             mgm2           months 
             289              150             1178              345              755              806              265             1093             1490 
     multicenter     multivariate           nausea         negative      neoadjuvant      neutropenia              new             node     nodepositive 
             126              142              239              233              289              234              171              188              199 
           nodes           number        objective         observed         obtained         occurred              one         operable             oral 
             289              276              357              571              127              260              566              149              274 
          orally          outcome         outcomes          overall       paclitaxel          partial          patient         patients              per 
             148              215              120              962              397              282              340             8041              218 
       performed           period            phase          placebo             plus            point       population         positive   postmenopausal 
             227              150              477              474              622              122              150              469              589 
       potential       predictive    premenopausal          present         previous       previously          primary            prior     progesterone 
             107              161              303              151              136              219              711              305              113 
      prognostic      progression  progressionfree      prospective          purpose          quality     radiotherapy       randomised       randomized 
             232              458              158              176              432              188              244              249             1046 
        randomly            range             rate            rates            ratio          receive         received        receiving         receptor 
             377              211              816              420              300              559              867              474              506 
receptorpositive       recurrence          reduced        reduction          regimen         regimens          relapse          related         relative 
             152              337              231              244              482              325              188              108              171 
        reported     respectively         response        responses          results             risk           safety           second        secondary 
             231              700             1749              268             1286              603              265              134              158 
            seen            serum          setting            seven           severe           showed            shown             side      significant 
             199              315              128              108              164              374              117              167             1039 
   significantly          similar           single              six             size           stable            stage         standard      statistical 
             902              405              149              261              174              154              259              274              106 
   statistically           status          studied          studies            study         subgroup          suggest         superior          support 
             268              538              116              286             1557              131              135              138              125 
         surgery         survival         systemic        tamoxifen            terms             test          therapy            three             time 
             406             1898              134             1630              128              146             1499              564              759 
          tissue        tolerated            total       toxicities         toxicity          treated        treatment       treatments            trial 
             164              220              393              168              790              831             2729              165             1135 
          trials            tumor           tumors              two              use             used            using            value           versus 
             282              612              506              889              321              333              339              147              570 
        vomiting           weekly            weeks             well          whereas          whether           within          without            women 
             174              262              726              328              173              235              172              306             1474 
            year            years 
             185             1143 
> max(csAbstract)
[1] 8041
> max(csAbstract)
[1] 8041
> which.max(csAbstract)
patients 
     215 
> colnames(dtmTitle) = paste0("T", colnames(dtmTitle))
> colnames(dtmAbstract) = paste0("A", colnames(dtmAbstract))
> dtm = cbind(dtmTitle, dtmAbstract)
> dtm$trial = trials$trial
> ncol(dtm)
[1] 367
> library(caTools)
> set.seed(144)
> spl = sample.split(dtm$trial, 0.7)
> train = subset(dtm, spl == TRUE)
> test = subset(dtm, spl == FALSE)
> table(train)
Error in table(train) : attempt to make a table with >= 2^31 elements
> table(train$trial)

  0   1 
730 572 
> 572/(730+572)
[1] 0.4393241
> 1-0.4393241
[1] 0.5606759
> library(rpart)
> library(rpart.plot)
> trialCART = rpart(trial~.,data = train,method="class")
> summary(trialCART)
Call:
rpart(formula = trial ~ ., data = train, method = "class")
  n= 1302 

          CP nsplit rel error    xerror       xstd
1 0.35489510      0 1.0000000 1.0000000 0.03130819
2 0.10139860      1 0.6451049 0.6451049 0.02842840
3 0.02272727      2 0.5437063 0.5839161 0.02754923
4 0.01048951      5 0.4720280 0.5314685 0.02668705
5 0.01000000      7 0.4510490 0.5174825 0.02643890

Variable importance
          Tphase            Amgm2             Tiii        Asurvival     Aneutropenia             Ambc           Aphase      Atoxicities          Tversus 
              29               11                9                7                5                4                4                3                3 
        Aoverall     Adiseasefree Tcyclophosphamid          Tbreast          Amedian      Apredictive             A500        Afollowup          Ahazard 
               3                2                2                2                2                2                2                1                1 
     Aepirubicin     Adoxorubicin      Aexpression      Aassociated      Aprognostic           Aevery 
               1                1                1                1                1                1 

Node number 1: 1302 observations,    complexity param=0.3548951
  predicted class=0  expected loss=0.4393241  P(node) =1
    class counts:   730   572
   probabilities: 0.561 0.439 
  left son=2 (1005 obs) right son=3 (297 obs)
  Primary splits:
      Tphase    < 0.5 to the left,  improve=124.62490, (0 missing)
      Atoxicity < 0.5 to the left,  improve= 98.40074, (0 missing)
      Amgm2     < 0.5 to the left,  improve= 98.09349, (0 missing)
      Aevery    < 0.5 to the left,  improve= 72.81706, (0 missing)
      Aresponse < 0.5 to the left,  improve= 71.78619, (0 missing)
  Surrogate splits:
      Tiii         < 0.5 to the left,  agree=0.840, adj=0.300, (0 split)
      Aneutropenia < 0.5 to the left,  agree=0.807, adj=0.155, (0 split)
      Ambc         < 0.5 to the left,  agree=0.803, adj=0.135, (0 split)
      Aphase       < 0.5 to the left,  agree=0.803, adj=0.135, (0 split)
      Atoxicities  < 0.5 to the left,  agree=0.798, adj=0.114, (0 split)

Node number 2: 1005 observations,    complexity param=0.1013986
  predicted class=0  expected loss=0.320398  P(node) =0.7718894
    class counts:   683   322
   probabilities: 0.680 0.320 
  left son=4 (875 obs) right son=5 (130 obs)
  Primary splits:
      Amgm2             < 0.5 to the left,  improve=48.42271, (0 missing)
      Asurvival         < 0.5 to the left,  improve=45.92267, (0 missing)
      Tversus           < 0.5 to the left,  improve=45.55312, (0 missing)
      Atoxicity         < 0.5 to the left,  improve=43.94031, (0 missing)
      Acyclophosphamide < 0.5 to the left,  improve=41.05959, (0 missing)
  Surrogate splits:
      A500         < 0.5 to the left,  agree=0.889, adj=0.138, (0 split)
      Aepirubicin  < 1.5 to the left,  agree=0.884, adj=0.100, (0 split)
      Adoxorubicin < 2.5 to the left,  agree=0.882, adj=0.085, (0 split)
      Aevery       < 1.5 to the left,  agree=0.877, adj=0.046, (0 split)
      Adocetaxel   < 5.5 to the left,  agree=0.876, adj=0.038, (0 split)

Node number 3: 297 observations,    complexity param=0.01048951
  predicted class=1  expected loss=0.1582492  P(node) =0.2281106
    class counts:    47   250
   probabilities: 0.158 0.842 
  left son=6 (16 obs) right son=7 (281 obs)
  Primary splits:
      Tbreast  < 0.5 to the left,  improve=9.473778, (0 missing)
      Arisk    < 1.5 to the right, improve=7.003397, (0 missing)
      Alevels  < 1.5 to the right, improve=5.016553, (0 missing)
      Alife    < 0.5 to the right, improve=5.016553, (0 missing)
      Aquality < 0.5 to the right, improve=4.519316, (0 missing)
  Surrogate splits:
      Aincrease     < 1.5 to the right, agree=0.953, adj=0.125, (0 split)
      Aadministered < 2.5 to the right, agree=0.949, adj=0.062, (0 split)

Node number 4: 875 observations,    complexity param=0.02272727
  predicted class=0  expected loss=0.2605714  P(node) =0.672043
    class counts:   647   228
   probabilities: 0.739 0.261 
  left son=8 (518 obs) right son=9 (357 obs)
  Primary splits:
      Asurvival         < 0.5 to the left,  improve=31.80802, (0 missing)
      Tversus           < 0.5 to the left,  improve=30.64761, (0 missing)
      Acyclophosphamide < 0.5 to the left,  improve=30.09940, (0 missing)
      Amedian           < 0.5 to the left,  improve=28.52596, (0 missing)
      Amethotrexate     < 0.5 to the left,  improve=21.96915, (0 missing)
  Surrogate splits:
      Aoverall     < 0.5 to the left,  agree=0.750, adj=0.387, (0 split)
      Adiseasefree < 0.5 to the left,  agree=0.725, adj=0.325, (0 split)
      Amedian      < 0.5 to the left,  agree=0.689, adj=0.238, (0 split)
      Afollowup    < 0.5 to the left,  agree=0.673, adj=0.199, (0 split)
      Ahazard      < 0.5 to the left,  agree=0.656, adj=0.157, (0 split)

Node number 5: 130 observations,    complexity param=0.01048951
  predicted class=1  expected loss=0.2769231  P(node) =0.09984639
    class counts:    36    94
   probabilities: 0.277 0.723 
  left son=10 (8 obs) right son=11 (122 obs)
  Primary splits:
      Apredictive < 0.5 to the right, improve=6.098424, (0 missing)
      Atoxicity   < 0.5 to the left,  improve=4.884537, (0 missing)
      Arate       < 1.5 to the left,  improve=4.514369, (0 missing)
      Tbreast     < 0.5 to the left,  improve=4.421188, (0 missing)
      Tversus     < 0.5 to the left,  improve=4.387930, (0 missing)
  Surrogate splits:
      Aexpression < 0.5 to the right, agree=0.969, adj=0.500, (0 split)
      Aassociated < 1.5 to the right, agree=0.962, adj=0.375, (0 split)
      Aprognostic < 1.5 to the right, agree=0.962, adj=0.375, (0 split)
      Aevaluated  < 1.5 to the right, agree=0.954, adj=0.250, (0 split)
      Aher2       < 0.5 to the right, agree=0.954, adj=0.250, (0 split)

Node number 6: 16 observations
  predicted class=0  expected loss=0.3125  P(node) =0.01228879
    class counts:    11     5
   probabilities: 0.688 0.312 

Node number 7: 281 observations
  predicted class=1  expected loss=0.1281139  P(node) =0.2158218
    class counts:    36   245
   probabilities: 0.128 0.872 

Node number 8: 518 observations
  predicted class=0  expected loss=0.1486486  P(node) =0.3978495
    class counts:   441    77
   probabilities: 0.851 0.149 

Node number 9: 357 observations,    complexity param=0.02272727
  predicted class=0  expected loss=0.4229692  P(node) =0.2741935
    class counts:   206   151
   probabilities: 0.577 0.423 
  left son=18 (307 obs) right son=19 (50 obs)
  Primary splits:
      Tversus           < 0.5 to the left,  improve=13.20897, (0 missing)
      Acyclophosphamide < 0.5 to the left,  improve=12.88702, (0 missing)
      Trespons          < 0.5 to the right, improve=11.71896, (0 missing)
      Aduration         < 0.5 to the left,  improve=11.53291, (0 missing)
      Tcyclophosphamid  < 0.5 to the left,  improve=11.35870, (0 missing)
  Surrogate splits:
      Avomiting    < 0.5 to the left,  agree=0.871, adj=0.08, (0 split)
      Tcombin      < 1.5 to the left,  agree=0.868, adj=0.06, (0 split)
      Tdoxorubicin < 1.5 to the left,  agree=0.866, adj=0.04, (0 split)
      Ttamoxifen   < 1.5 to the left,  agree=0.866, adj=0.04, (0 split)
      Aevaluable   < 1.5 to the left,  agree=0.866, adj=0.04, (0 split)

Node number 10: 8 observations
  predicted class=0  expected loss=0.125  P(node) =0.006144393
    class counts:     7     1
   probabilities: 0.875 0.125 

Node number 11: 122 observations
  predicted class=1  expected loss=0.2377049  P(node) =0.093702
    class counts:    29    93
   probabilities: 0.238 0.762 

Node number 18: 307 observations,    complexity param=0.02272727
  predicted class=0  expected loss=0.3680782  P(node) =0.2357911
    class counts:   194   113
   probabilities: 0.632 0.368 
  left son=36 (282 obs) right son=37 (25 obs)
  Primary splits:
      Tcyclophosphamid  < 0.5 to the left,  improve=10.154760, (0 missing)
      Acycles           < 0.5 to the left,  improve= 9.421539, (0 missing)
      Acyclophosphamide < 0.5 to the left,  improve= 8.844422, (0 missing)
      Aregimen          < 0.5 to the left,  improve= 8.734039, (0 missing)
      Trespons          < 0.5 to the right, improve= 8.677642, (0 missing)
  Surrogate splits:
      Acourses    < 5.5 to the left,  agree=0.925, adj=0.08, (0 split)
      Aday        < 3.5 to the left,  agree=0.925, adj=0.08, (0 split)
      Apredictive < 2.5 to the left,  agree=0.925, adj=0.08, (0 split)
      Acmf        < 5.5 to the left,  agree=0.922, adj=0.04, (0 split)
      Aeight      < 1.5 to the left,  agree=0.922, adj=0.04, (0 split)

Node number 19: 50 observations
  predicted class=1  expected loss=0.24  P(node) =0.03840246
    class counts:    12    38
   probabilities: 0.240 0.760 

Node number 36: 282 observations
  predicted class=0  expected loss=0.3297872  P(node) =0.2165899
    class counts:   189    93
   probabilities: 0.670 0.330 

Node number 37: 25 observations
  predicted class=1  expected loss=0.2  P(node) =0.01920123
    class counts:     5    20
   probabilities: 0.200 0.800 

> prp(trialCART)
> predTrain = predict(trialCart)[,2]
Error in predict(trialCart) : object 'trialCart' not found
> predTrain = predict(trialCART)[,2]
> summary(predTrain)
   Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
 0.1250  0.1486  0.3298  0.4393  0.7623  0.8719 
> predTrain = predict(trialCART)
> summary(predTrain)
       0                1         
 Min.   :0.1281   Min.   :0.1250  
 1st Qu.:0.2377   1st Qu.:0.1486  
 Median :0.6702   Median :0.3298  
 Mean   :0.5607   Mean   :0.4393  
 3rd Qu.:0.8514   3rd Qu.:0.7623  
 Max.   :0.8750   Max.   :0.8719  
> table(train$trial, predTrain >= 0.5)
Error in table(train$trial, predTrain >= 0.5) : 
  all arguments must have the same length
> table(trials$trial, predTrain >= 0.5)
Error in table(trials$trial, predTrain >= 0.5) : 
  all arguments must have the same length
> predTest = predict(trialCART, newdata=test)[,2]
> predTest = predict(trialCART, newdata=test)
> table(test$trial, predTest >= 0.5)
Error in table(test$trial, predTest >= 0.5) : 
  all arguments must have the same length
> predTest = predict(trialCART, newdata=test)[,2]
> table(test$trial, predTest >= 0.5)
   
    FALSE TRUE
  0   274   39
  1    96  149
> #probablity 
> (274+149)/(274+96+39+149)
[1] 0.7580645
> 
> save.image("C:\\Users\\Saransh\\Documents\\R DATA\\CLINICAL DATA\\CLINICAL Trials")
> ##### THE MODEL HAS BEEN SOLVED USING CART MODEL, GIVING AN EFFICIENCE OF 76% CORRECT OUTCOME ####
